ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10 Press release LEIDEN, Pays-Bas et CAMBRIDGE, Massachusetts, 18 déc. 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. December 18, 2018
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 05, 2021
ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong Press release Key Updates August 28, 2017
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 11, 2018
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Press release LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 18, 2019
ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients Press release Key updates April 27, 2017
L’Agence européenne des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10 Press release Cet accès s'appuie sur une analyse intermédiaire positive des données cliniques et des données précliniques à ce jour July 29, 2019
ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. August 12, 2019
ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO Press release LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. October 07, 2019
ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target Press release Yarrow Biotechnology, Inc., a newly formed biotechnology company backed by RTW Investments, LP, will lead development of the program ProQR May 04, 2021